Oncology

Atreca secured USD 125 Million when solid tumor trial comes into picture California based company, Atreca has bagged USD 125 million to establish its R&D activities. As the company gears up, the series C round enters, to move its lead solid tumor drug into the clinic.  Atreca has set up its credentials through VC rounds that added USD 91 million to its funds and engrossed the backing of investors like GlaxoSmithKline and the Bill & Melinda Gates Foundation. GSK and the Gates Foundation commenced working with Atreca too. OncoResponse bags USD 40 Million for cancer patient-sourced antibodies OncoResponse has secured USD 40 million in second-round financing to dev...